IntroductionNatural Killer Cells (NK cells) have a critical role in innate immune system. The new generation of genetically modified NK cells are CAR-NKs. They can function as a tumor-specific standardized characterized products. Due to their ability in specific tumor recognition, he have decided to do a comprehensive study in this area.MethodsRelevant English-language literature were searched and retrieved from PubMed search engine and https://clinicaltrials.gov (2008-2018). The following keywords were used: CAR-NK ,
CAR-Natural Killer Cells , Cancer and Personalized medicine .ResultsUntil now, 4 clinical trials have been started in using CAR-NK cells for cancer treatment. Two of them focused on neuroblastoma in Texas Children s Hospital. One of them was withdrawn. 24 patients were recruited for the second one. This group wanted to use GD2-specific CARS and for further antitumor activity added another gene expressing IL-15. They have not reported any result so far. The third one was started by MD Anderson cancer center. They have recruited 36 patients (7-80 years old) with relapsed/refractory CD19+ B lymphoid malignancies. They wanted to use CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood natural killer (CB-NK) cells in patients. No reported no results until now. And the last study was again begun by MD Anderson cancer center. They aimed to assess the immunotherapy with ex vivo-expanded cord blood-derived CAR-NK cells combined with high-dose chemotherapy and autologous stem cell transplantation for patients (18-70 years old) with B-cell lymphoma and they announced no results so far.ConclusionBased on the results of in-vitro and pre-clinical studies, the specifity of CAR-NK cells to cancer cells has made them a valuable candidate for clinical trials. However, the use of CAR-NK cells needs more examination to be proofed as a suitable therapeutic approach.Conflict of InterestThe authors declare no conflict of interest.